CN Patent

CN114306629A — 具有增加的nep稳定性的控制释放cnp激动剂

Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2022-04-12 · 4y expired

What this patent protects

本发明涉及控制释放CNP激动剂，其在体外NEP降解测定法中具有比相应的释放的CNP激动剂至少长5倍的降解半衰期，本发明还涉及包含所述控制释放CNP激动剂的药物组合物、它们的用途和治疗方法。

USPTO Abstract

本发明涉及控制释放CNP激动剂，其在体外NEP降解测定法中具有比相应的释放的CNP激动剂至少长5倍的降解半衰期，本发明还涉及包含所述控制释放CNP激动剂的药物组合物、它们的用途和治疗方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN114306629A
Jurisdiction: CN
Classification: —
Expires: 2022-04-12
Drug substance claim: No
Drug product claim: No
Assignee: Ascendis Pharma Endocrinology Division AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.